upwardly innovative
Propella develops innovative, best-in-class therapeutics with an eye toward mitigated development risk. We use proven science, a scalable methodical therapeutic design approach, and drug development insights to produce products that are more effective, safer, and smarter.
We are a development-stage subsidiary of Astellas Pharmaceuticals, dedicated to bringing to market first- or best-in-class drugs that utilize a proven mechanism of action. Our lead product candidate, PRL-02 (abiraterone decanoate), protected by issued international composition of matter patents wholly owned by us, is currently in a phase 1 dose-escalation study for metastatic prostate cancer. We are actively advancing additional oncology therapies through our discovery process and our relationship with Astellas colleagues.